CAM
CBAY

Connacht Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Connacht Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$179K Sell
11,986
-22,549
-65% -$299K 1.06% 45
2023
Q2 		$378K Sell
34,535
-4,592
-12% -$42.8K 0.52% 58
2023
Q1 		$341K Buy
+39,127
New +$313K 0.15% 104

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Connacht Asset Management's CBAY Position: Q3 2023 in Review

Connacht Asset Management reduced its Cymabay Therapeutics (CBAY) stake by 65% in Q3 2023, selling an estimated $299K and leaving 11,986 shares worth $179K. The position accounts for 1.06% of the portfolio, ranked #45.

Connacht Asset Management first reported a position in CBAY in Q1 2023 and has held it in 3 quarters since. The position peaked at $378K in Q2 2023. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

  • Connacht Asset Management held 11,986 shares of Cymabay Therapeutics worth $179K as of Q3 2023.
  • Connacht Asset Management sold 22,549 Cymabay Therapeutics shares in Q3 2023, an estimated $299K.
  • Cymabay Therapeutics made up 1.06% of Connacht Asset Management's portfolio in Q3 2023, its #45 holding.
  • Connacht Asset Management first reported a position in Cymabay Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • Connacht Asset Management's Cymabay Therapeutics position peaked at $378K in Q2 2023.
  • 189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.